Startseite Maternal serum endocan concentrations are elevated in patients with preterm premature rupture of membranes
Artikel
Lizenziert
Nicht lizenziert Erfordert eine Authentifizierung

Maternal serum endocan concentrations are elevated in patients with preterm premature rupture of membranes

  • Ali Ovayolu ORCID logo EMAIL logo , Gamze Ovayolu , Erbil Karaman , Tuncay Yuce , Abdulkadir Turgut und Nuray Bostancıeri
Veröffentlicht/Copyright: 15. März 2019

Abstract

Objectives

To evaluate the maternal serum endocan levels in pregnant women complicated by preterm premature rupture of membranes (PPROM) and to compare the results with healthy pregnancies.

Methods

This cohort study included 31 pregnant women with PPROM and 34 gestational age-matched healthy subjects in the third trimester of pregnancy. The blood for analysis was obtained on the day of diagnosis and serum endocan levels were measured using a commercially available enzyme-linked immunosorbent assay (ELISA) kit. The pregnant women were observed until the delivery and perinatal data were noted.

Results

No significant differences regarding maternal age, body mass index, gravidity, parity and gestational age at sampling were observed (P > 0.05). Mean serum endocan level was significantly higher in the PPROM group than in healthy controls (1490 ± 632 pg/mL vs. 972 ± 586 pg/mL, respectively; P: 0.001). Serum endocan concentration was positively correlated with C-reactive protein (CRP) (r = 0.754, P < 0.001) and white blood cells count (WBC) (r = 0.712, P:0.001). The receiver operating characteristic (ROC) curve analysis showed that endocan with a cut-off point of 1198 ng/dL indicated women with PPROM with sensitivity of 64.5% and specificity of 35.1% (area under curve 0.731, confidence interval 0.61–0.85).

Conclusion

Serum endocan level was significantly elevated in the PPROM patients than in healthy controls. The endocan level may be a useful indicator of endothelial dysfunction/inflammation in PPROM cases.

  1. Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

  2. Research funding: None declared.

  3. Employment or leadership: None declared.

  4. Honorarium: None declared.

  5. Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

References

1. Mercer B, Milluzzi C, Collin M. Periviable birth at 20 to 26 weeks of gestation: proximate causes, previous obstetric history and recurrence risk. Am J Obstet Gynecol 2005;193:1175–80.10.1016/j.ajog.2005.05.040Suche in Google Scholar

2. Poma PA. Premature rupture of membranes. J Natl Med Assoc 1996;88:27.Suche in Google Scholar

3. Tchirikov M, Schlabritz-Loutsevitch N, Maher J, Buchmann J, Naberezhnev Y, Winarno AS, et al. Mid-trimester preterm premature rupture of membranes (PPROM): etiology, diagnosis, classification, international recommendations of treatment options and outcome. J Perinat Med 2018;46:465–88.10.1515/jpm-2017-0027Suche in Google Scholar

4. Mercer BM. Preterm premature rupture of the mem- branes. Obstet Gynecol 2003;101:178–93.Suche in Google Scholar

5. Huang S, Xia W, Sheng X, Qiu L, Zhang B, Chen T, et al. Maternal lead exposure and premature rupture of membranes: a birth cohort study in China. BMJ Open 2018;8:e021565.10.1136/bmjopen-2018-021565Suche in Google Scholar

6. Cetin O, Karaman E, Boza B, Cim N, Erel O, Alisik M, et al. The maternal thiol/disulfide homeostasis does not change in pregnancies complicated by preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med 2018;31:783–90.10.1080/14767058.2017.1297413Suche in Google Scholar

7. Savasan ZA, Romero R, Chaiworapongsa T, Kusanovic JP, Kim SK, Mazaki-Tovi S, et al. Evidence in support of a role for anti-angiogenic factors in preterm prelabor rupture of membranes. J Matern Fetal Neonatal Med 2010;23:828–41.10.3109/14767050903440471Suche in Google Scholar

8. Kucukgul S, Ozkan ZS, Yavuzkir S, Ilhan N. Investigation of the maternal and cord plasma levels of IL-1 beta, TNF-alpha and VEGF in early membrane rupture. J Matern Fetal Neonatal Med 2016;29:2157–60.10.3109/14767058.2015.1077511Suche in Google Scholar

9. Arias F, Rodriquez L, Rayne SC, Kraus FT. Maternal placental vasculopathy and infection: two distinct subgroups among patients with preterm labor and preterm ruptured membranes. Am J Obstet Gynecol 1993;168:585–91.10.1016/0002-9378(93)90499-9Suche in Google Scholar

10. Kim YM, Chaiworapongsa T, Gomez R, Bujold E, Yoon BH, Rotmensch S, et al. Failure of physiologic transformation of the spiral arteries in the placental bed in preterm premature rupture of membranes. Am J Obstet Gynecol 2002;187: 1137–42.10.1067/mob.2002.127720Suche in Google Scholar PubMed

11. Labarrere CA, DiCarlo HL, Bammerlin E, Hardin JW, Kim YM, Chaemsaithong P, et al. Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. Am J Obstet Gynecol 2017;216:287.e1–e16.10.1016/j.ajog.2016.12.029Suche in Google Scholar PubMed PubMed Central

12. Béchard D, Gentina T, Delehedde M, Scherpereel A, Lyon M, Aumercier M, et al. Endocan is a novel chondroitin sulfate/dermatan sulfate proteoglycan that promotes hepatocyte growth factor/scatter factor mitogenic activity. J Biol Chem 2001;276:48341–9.10.1074/jbc.M108395200Suche in Google Scholar PubMed

13. Schuitemaker JHN, Cremers TIFH, Van Pampus MG, Scherjon SA, Faas MM. Changes in endothelial cell specific molecule 1 plasma levels during preeclamptic pregnancies compared to healthy pregnancies. Pregnancy Hypertens 2018;12:58–64.10.1016/j.preghy.2018.02.012Suche in Google Scholar PubMed

14. Bicer M, Guler A, Unal Kocabas G, Imamoglu C, Baloglu A, Bilgir O, et al. Endocan is a predictor of increased cardiovascular risk in women with polycystic ovary syndrome. Endocr Res 2017;42:145–53.10.1080/07435800.2016.1255896Suche in Google Scholar PubMed

15. Sarrazin S, Adam E, Lyon M, Depontieu F, Motte V, Landolfi C, et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006;1765:25–37.10.1016/j.bbcan.2005.08.004Suche in Google Scholar PubMed

16. Cakmak M, Yilmaz H, Bağlar E, Darcin T, Inan O, Aktas A, et al. Serum levels of endocan correlate with the presence and severity of pre-eclampsia. Clin Exp Hypertens 2016;38:137–42.10.3109/10641963.2015.1060993Suche in Google Scholar PubMed

17. Szpera-Gozdziewicz A, Kosicka K, Gozdziewicz T, Krzyscin M, Wirstlein P, Siemiatkowska A, et al. Maternal serum endocan concentration in pregnancies complicated by intrauterine growth restriction. Reprod Sci 2018;26:370–6.10.1177/1933719118773480Suche in Google Scholar PubMed

18. Bechard D, Meignin V, Scherpereel A, Oudin S, Kervoaze G, Bertheau P, et al. Characterization of the secreted form of endothelial- cell-specific molecule 1 by specific monoclonal antibo- dies. J Vasc Res 2000;37:417–25.10.1159/000025758Suche in Google Scholar PubMed

19. Béchard D, Scherpereel A, Hammad H, Gentina T, Tsicopoulos A, Aumercier M, et al. Human endothelial-cell specific molecule-1 binds directly to the integrin CD11a/CD18 (LFA-1) and blocks binding to intercellular adhesion molecule-1. J Immunol 2001;167:3099–106.10.4049/jimmunol.167.6.3099Suche in Google Scholar PubMed

20. Scherpereel A, Depontieu F, Grigoriu B, Cavestri B, Tsicopoulos A, Gentina T, et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006;34:532–7.10.1097/01.CCM.0000198525.82124.74Suche in Google Scholar

21. Adekola H, Romero R, Chaemsaithong P, Korzeniewski SJ, Dong Z, Yeo L, et al. Endocan, a putative endothelial cell marker, is elevated in preeclampsia, decreased in acute pyelonephritis, and unchanged in other obstetrical syndromes. J Matern Fetal Neonatal Med 2015;28: 1621–32.10.3109/14767058.2014.964676Suche in Google Scholar PubMed PubMed Central

22. Menon R, Richardson LS. Preterm prelabor rupture of the membranes: a disease of the fetal membranes. Semin Perinatol 2017;41:409–19.10.1053/j.semperi.2017.07.012Suche in Google Scholar PubMed PubMed Central


Article note:

This manuscript was presented as an oral presentation at 10th Congress on Ultrasound in Obstetrics and Gynecology between 27th–30th September, 2018 at Hilton Dalaman, Sarıgerme, Turkey.


Received: 2018-11-30
Accepted: 2019-02-02
Published Online: 2019-03-15
Published in Print: 2019-07-26

©2019 Walter de Gruyter GmbH, Berlin/Boston

Artikel in diesem Heft

  1. Frontmatter
  2. Editorial
  3. Preterm premature rupture of membranes (PPROM)
  4. Original Articles – Obstetrics
  5. The value of amniotic fluid analysis in patients with suspected clinical chorioamnionitis
  6. Patients with acute cervical insufficiency without intra-amniotic infection/inflammation treated with cerclage have a good prognosis
  7. Maternal serum endocan concentrations are elevated in patients with preterm premature rupture of membranes
  8. The earlier the gestational age, the greater the intensity of the intra-amniotic inflammatory response in women with preterm premature rupture of membranes and amniotic fluid infection by Ureaplasma species
  9. Assessment of maternal GBS colonization and early-onset neonatal disease rate for term deliveries: a decade perspective
  10. Clinical importance of the 75-g glucose tolerance test (GTT) in the prediction of large for gestational age (LGA) fetuses in non-diabetic pregnancies
  11. Expression of genes involved in inflammation and growth – does sampling site in human full-term placenta matter?
  12. Impact of cell-free fetal DNA on invasive prenatal diagnostic tests in a real-world public setting
  13. Perinatal outcome in gestational diabetes according to different diagnostic criteria
  14. Original Articles – Fetus
  15. Change in fetal behavior in response to vibroacoustic stimulation
  16. Diagnostic accuracy of isolated clubfoot in twin compared to singleton gestations
  17. Original Article – Newborn
  18. Usefulness of transcutaneous bilirubin assessment measured in non-photo-exposed skin to guide the length of phototherapy: an observational study
  19. Letters to the Editor
  20. Methodological issues on the clinical importance of the 75-g glucose tolerance test (GTT) in the prediction of large for gestational age (LGA) fetuses in non-diabetic pregnancies
  21. Reply to the Letter to the Editor: methodological issues on the clinical importance of the 75-g glucose tolerance test (GTT) in the prediction of large-for-gestational-age (LGA) fetuses in non-diabetic pregnancies
Heruntergeladen am 26.11.2025 von https://www.degruyterbrill.com/document/doi/10.1515/jpm-2018-0401/html?lang=de
Button zum nach oben scrollen